• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mylan clarifies $104 profit on $600 EpiPens

September 27, 2016 By Sarah Faulkner

Mylan clarifies $104 profit on $600 EpiPensMylan (NSDQ:MYL) acknowledged that the $104 profit it reported to Congress included taxes, after the Wall Street Journal reported that the company applied the statutory U.S. tax rate of 37.5% to calculate its profits for testimony before the Senate, according to Reuters.

“Without the tax-related reduction, Mylan’s profits on the EpiPen 2-pack would be closer to $160, or 60% higher than the figure the company gave Congress,” the journal reported.

The company came under fire in August for raising the price of its epinephrine auto-injector to $600, more than 500%, since it acquired the device in 2007. Last week, Mylan CEO Heather Bresch testified before the Senate after politicians called for the company to be more transparent with its pricing strategy.

Mylan filed a profitability analysis with the SEC today which detailed the tremendous growth the company has seen with the EpiPen since 2008. In 2008, Mylan sold $184 million worth of EpiPens, or 4.3 million pens. That’s projected to double by the end of 2016, to $1.1 billion.

In 2008, net product profitability rang in at $3 million. Mylan predicts that by the end of 2016, EpiPen will bring in $419 million in net profitability. The profit margin has also grown in the past 8 years, from 57.1% in 2008 to 75% this year.

“Following Mylan’s recent testimony before the United States House of Representatives regarding EpiPen, Mylan is providing this analysis of the profitability in the United States of EpiPen as a supplement to its testimony,” the company wrote in the filing. “Mylan does not regularly provide profitability analyses for individual products and does not intend in the future to provide product level profitability analysis for EpiPen or to update this analysis.”

“We didn’t believe Mylan’s numbers last week during their CEO’s testimony, and we don’t believe them this week either,” Rep. Elijah Cummings (D-Md.), the ranking Democrat on the committee, said in a statement.

Mylan said yesterday that it is standard practice to include taxes in a profitability analysis. Mylan’s overall effective tax rate was 7.4% in 2015, according to the SEC filing.  

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Wall Street Beat Tagged With: Capitol Hill, Mylan

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS